O. Bouché

发表

Feasibility and Impact of Adapted Physical Activity (APA) in Cancer Outpatients Beginning Medical Anti-Tumoral Treatment: The UMA-CHAPA Study

Anne Quinquenel, A. Lemoine, M. Perrier, 2022, Cancers.

Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral Neuropathy

C. Lambert, S. Melnikov, O. Bouché, 2021, Frontiers in Pharmacology.

[Gastrointestinal stromal tumors (GIST)<5 cm in size: review of the literature and expert propositions for clinical management].

R. Guimbaud, O. Bouché, J. Chayvialle, 2010, Gastroenterologie clinique et biologique.

Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients.

P. Laurent-Puig, A. Griffiths, H. Blons, 2013, Clinical chemistry.

Identification of Raman spectroscopic markers for the characterization of normal and adenocarcinomatous colonic tissues.

M. Manfait, O. Bouché, M. Diebold, 2009, Critical reviews in oncology/hematology.

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

A. Lièvre, P. Laurent-Puig, M. Ychou, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives.

O. Bouché, C. Hoeffel, C. Marcus, 2009, Critical reviews in oncology/hematology.

Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27).

A. Lièvre, M. Ychou, J. Taïeb, 2020, Clinical colorectal cancer.

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial

T. Conroy, P. Laurent-Puig, M. Ychou, 2014, British Journal of Cancer.

A New Rapid and Sensitive LC-MS Assay for the Determination of Sorafenib in Plasma: Application to a Patient Undergoing Hemodialysis

O. Bouché, J. Bard, C. Bobin-Dubigeon, 2011, Therapeutic drug monitoring.

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Pierre Michel, Olivier Bouché, Jaafar Bennouna, 2011, The New England journal of medicine.

Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.

David Goldstein, Florence Huguet, Franck Bonnetain, 2016, JAMA.

Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial.

T. Conroy, M. Ducreux, D. Peiffert, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

J. Reid, A. Lièvre, P. Laurent-Puig, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BRAFV600E Gene Mutation in Colonic Adenocarcinomas. Immunohistochemical Detection Using Tissue Microarray and Clinicopathologic Characteristics: An 86 Case Series

O. Bouché, R. Kianmanesh, M. Diebold, 2016, Applied immunohistochemistry & molecular morphology : AIMM.

Filiform polyposis: A benign entity? Case report and literature review.

O. Bouché, M. Diebold, C. Boulagnon, 2014, Pathology, research and practice.

Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy

Sabine Tejpar, Bruno Landi, Simona Rossi, 2014, Clinical Cancer Research.

Clinical Relevance of KRAS-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy

Bruno Landi, Karla Perez-Toralla, Philippe Nizard, 2014, Clinical Cancer Research.

Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial

M. Ychou, M. Stern, F. Bidard, 2019, Cells.

Incidental gastrointestinal 18F-Fluorodeoxyglucose uptake associated with lung cancer

D. Papathanassiou, M. Brasseur, H. Vallerand, 2015, BMC Pulmonary Medicine.

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

R. Greil, S. Kubicka, E. Van Cutsem, 2013, The Lancet. Oncology.

Dynapenia in digestive cancer outpatients: association with markers of functional and nutritional status (the FIGHTDIGO study)

M. Perrier, C. Mazza, M. Brasseur, 2021, Supportive Care in Cancer.

Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Bernard Leduc, Franck Bonnetain, Olivier Bouché, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?

L. Collette, G. Calais, T. Conroy, 2012, European journal of cancer.

Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

T. Conroy, Y. Bécouarn, O. Bouché, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial.

T. Conroy, M. Ducreux, O. Bouché, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study.

B. Chauffert, J. Bosset, P. Maingon, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Liver angulometry: a simple method to estimate liver volume and ratios.

S. Msika, O. Bouché, D. Sommacale, 2013, HPB : the official journal of the International Hepato Pancreato Biliary Association.

Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial.

T. Conroy, M. Ychou, M. Ducreux, 2010 .

The tumor burden of metastatic colorectal cancer patients at initial diagnosis, pre- versus post-Covid-19 lockdown

M. Ychou, E. Assenat, D. Smith, 2021, medRxiv.

[Recommendations for the management of GIST patients].

J. Blay, S. Bonvalot, J. Coindre, 2005, Bulletin du cancer.

Value of Contrast-Enhanced Ultrasound Quantification Criteria for Identifying Patients not Responding to Bevacizumab-Based Therapy for Colorectal Liver Metastases

J. Douillard, C. Borg, O. Bouché, 2017, Ultraschall in der Medizin - European Journal of Ultrasound.

Bleeding reflux esophagitis: a prospective 1-year study in a university hospital.

O. Bouché, G. Thiéfin, C. Merle, 2001 .

Bleeding reflux esophagitis: a prospective 1-year study in a university hospital

O. Bouché, G. Thiéfin, C. Merle, 2001, American Journal of Gastroenterology.

Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer

T. Conroy, Y. Bécouarn, O. Bouché, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.

M. Ychou, J. Douillard, F. Goldwasser, 2012, Clinical colorectal cancer.

An analysis of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer on survival in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question?

L. Collette, G. Calais, T. Conroy, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase l/lI, Open-label, Randomised Study of BIBF 1120 Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer

H. Staines, O. Bouché, J. Capdevila, 2011 .

Assessment of Baseline Clinical Predictive Factors of Response to Cetuximab-Irinotecan in Patients with Irinotecan-Refractory Metastatic Colorectal Cancer

T. Conroy, C. Fournier, O. Bouché, 2008, Oncology.

Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial.

T. Conroy, E. Van Cutsem, B. Nordlinger, 2005, The Lancet. Oncology.

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.

P. Rougier, O. Bouché, A. de Gramont, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in Fédération Francophone de Cancérologie Digestive (FFCD) trials.

M. Ducreux, O. Bouché, J. Taieb, 2021, European journal of cancer.

Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02).

I. Sobhani, O. Bouché, P. Michel, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomised Trial Comparing Three Different Schedules of Infusional 5FU and Raltitrexed Alone as First-Line Therapy in Metastatic Colorectal Cancer

J. Pignon, M. Ducreux, A. Dunant, 2006, Oncology.

Cost-Effectiveness Analysis of First-Line Chemotherapies in Metastatic Colorectal Cancer

J. Pignon, M. Ducreux, O. Bouché, 2007, Oncology.

Postoperative chemoradiotherapy after surgical resection of gastric adenocarcinoma: can LV5FU2 reduce the toxic effects of the MacDonald regimen? A report on 23 patients.

P. Rougier, O. Bouché, J. Seitz, 2005, Gastroenterologie clinique et biologique.

Randomized adjuvant study comparing two schemes of 5-fluorouracil and leucovorin in stage B2 and C colon adenocarcinoma: study design and preliminary safety results. Groupe d'Etude et de Recherche Clinique en Oncologie Radiotherapies.

M. Buyse, O. Bouché, P. Piedbois, 2001, Seminars in oncology.

Oxaliplatin-desensitization procedure is safe and feasible in an outpatient cancer unit in France

C. Mazza, M. Brasseur, D. Botsen, 2019, Supportive Care in Cancer.

Dynapenia could predict chemotherapy-induced dose-limiting neurotoxicity in digestive cancer patients

M. Perrier, C. Mazza, M. Brasseur, 2018, BMC Cancer.

Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial.

M. Ychou, G. Deplanque, Y. Bécouarn, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study".

O. Bouché, D. Vernerey, J. Taieb, 2022, Clinical colorectal cancer.

Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials.

R. Labianca, V. Torri, E. Van Cutsem, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nutrition and physical activity: French intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC, SFP-APA, SFNCM, AFSOS)

A. Lièvre, E. Fontaine, D. Quilliot, 2020, BMJ Supportive & Palliative Care.

High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study

M. Loriot, P. Rougier, O. Bouché, 2015, Molecular Cancer Therapeutics.

Irinotecan for the treatment of gastric cancer

C. Köhne, P. Rougier, O. Bouché, 2004 .

Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.

Christophe Hennequin, Bernard Denis, Pierre-Luc Etienne, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.

J. Bosset, B. Nordlinger, P. Rougier, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors

M. Ychou, B. Dréno, O. Bouché, 2012, Supportive Care in Cancer.

Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial

C. Lepage, O. Bouché, C. Pétorin, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial

J. Pignon, M. Ducreux, V. Boige, 2007, British Journal of Cancer.

Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients

J. Douillard, C. Borg, V. Gouilleux-Gruart, 2016, Clinical Pharmacokinetics.

Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high‐risk Stage II and III colon cancers? Three years' follow‐up results of the PRODIGE 22 phase II randomized multicentre trial

F. Brunetti, A. Lièvre, C. Lepage, 2021, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Greil, B. Chauffert, S. Barni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients.

A. Carrato, E. Van Cutsem, M. Ducreux, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic factors in patients with non resectable metastatic colorectal cancer in the era of targeted biotherapies: relevance of Köhne's risk classification.

O. Bouché, L. de Mestier, C. Delmas, 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Desmoid tumors located in the abdomen or associated with adenomatous polyposis: French intergroup clinical practice guidelines for diagnosis, treatment, and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR).

A. Gangi, S. Salas, S. Bonvalot, 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9).

C. Borel, C. Lepage, V. Boige, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment.

M. Ychou, Y. Bécouarn, R. Guimbaud, 2011, Clinics and research in hepatology and gastroenterology.

Metastatic colorectal carcinoma with signet-ring cells: Clinical, histological and molecular description from an Association des Gastro-Entérologues Oncologues (AGEO) French multicenter retrospective cohort.

W. Cacheux, O. Bouché, D. Tougeron, 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials.

D. Sargent, S. Thibodeau, P. Laurent-Puig, 2015 .

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

D. Sargent, M. Ychou, R. Goldberg, 2013, The Lancet.

Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.

Satoshi Morita, Yasuo Ohashi, Junichi Sakamoto, 2013, Journal of the National Cancer Institute.

Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: The prospective IPPEM study.

B. Delclaux, M. Dewolf, O. Bouché, 2022, Lung cancer.

[Pelvic MRI at 3.0 Tesla].

O. Bouché, C. Hoeffel, C. Marcus, 2009, Journal de radiologie.

Tertiary lymphoid structures in epithelioid malignant peritoneal mesothelioma are associated with neoadjuvant chemotherapy, but not with prognosis

F. Guyon, I. Villa, M. Pocard, 2021, Virchows Archiv.

Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study.

M. Ducreux, P. Rougier, O. Bouché, 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre

M. Ychou, P. Rougier, R. Guimbaud, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Experience of Gemcitabine plus Oxaliplatin Chemotherapy in Patients with Advanced Biliary Tract Carcinoma

F. Pruvot, C. Mariette, J. Triboulet, 2010, Chemotherapy.

Impact of primary tumour resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy: results from the multicenter, randomised trial Fédération Francophone de Cancérologie Digestive 9601.

J. Pignon, M. Ducreux, V. Boige, 2013, European journal of cancer.

Metastatic colorectal cancer.

C. Tournigand, T. Conroy, O. Bouché, 2006, Gastroenterologie clinique et biologique.

A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802)

M. Ychou, J. Douillard, Y. Bécouarn, 2005 .

Molecular description of ANGPT2 associated colorectal carcinoma.

C. Borg, O. Bouché, Stefano Kim, 2020, International journal of cancer.

Preoperative (preop) radiotherapy (RT) + 5FU/folinic acid (FA) in T3,4 rectal cancers: Preliminary results of the FFCD 9203 randomized trial

T. Conroy, M. Déjardin, J. Bosset, 2004 .

Signet Ring Cells and Efficacy of First-line Chemotherapy in Advanced Gastric or Oesogastric Junction Adenocarcinoma.

A. Duhamel, J. Salleron, E. Leteurtre, 2016, Anticancer research.

Pravastatin combination with Sorafenib does not improve survival in advanced Hepatocellular Carcinoma.

O. Bouché, J. Seitz, J. Jouve, 2019, Journal of hepatology.

Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD‐NADEGE cohort study of 347 patients

M. Pocard, G. Piessen, C. Lombard-Bohas, 2020, International journal of cancer.

Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000–05): Preliminary results

M. Ducreux, P. Rougier, O. Bouché, 2007 .

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results

O. Bouché, F. Retornaz, J. Taieb, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial

P. Laurent-Puig, O. Bouché, T. Mazard, 2021, Clinical Cancer Research.

Time to Surgery Does Not Influence Survival Outcome in Patients With Upfront Resected Pancreatic Adenocarcinoma

O. Bouché, J. Regimbeau, R. Kianmanesh, 2021 .

Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial.

F. Bidard, J. Pierga, O. Bouché, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C.

O. Bouché, G. Thiéfin, M. Diebold, 2005, Gastroenterologie clinique et biologique.

Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer.

C. Lepage, V. Jooste, O. Bouché, 2022, European journal of cancer.

RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study

P. Laurent-Puig, H. Blons, O. Bouché, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression of the Serrated Markers Annexin A10 or Gremlin1 in Colonic Adenocarcinomas: Morphology and Prognostic Values

O. Bouché, R. Kianmanesh, M. Diebold, 2020, Pathology & Oncology Research.

Small bowel adenocarcinoma: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).

M. Pocard, Y. Bécouarn, O. Bouché, 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors

M. Brasseur, O. Bouché, G. Deslée, 2015, BMC Cancer.

Safety of FOLFIRI + Durvalumab +/− Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59

C. Lepage, D. Botsen, O. Bouché, 2022, Biomedicines.

Bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wtKRAS metastatic colorectal cancer: A randomized phase II study (Prodige 18 –UNICANCER GI).

T. Conroy, G. Deplanque, C. Borg, 2016 .

Pesticides and pancreatic adenocarcinoma: A transversal epidemiological, environmental and mechanistic narrative review.

A. Carrier, O. Bouché, G. Reyes-Castellanos, 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial.

O. Bouché, L. Mineur, V. Le Brun-Ly, 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.

O. Bouché, F. Retornaz, J. Taieb, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Metastatic Gastrointestinal Cancer: Safety of Cisplatin Combined with Continuous 5-FU Versus Bolus 5-FU and Leucovorin (Methodology)

M. Ychou, J. Duffour, M. Ducreux, 2008 .

Survey on the management of skin toxicity associated with EGFR inhibitors amongst French Physicians

M. Ychou, B. Dréno, O. Bouché, 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm

M. Ychou, B. Dréno, M. Richard, 2012, Supportive Care in Cancer.

[Vascular and renal effects of anti-angiogenic therapy].

P. Rieu, S. Oudard, O. Bouché, 2008, Nephrologie & therapeutique.

Capecitabine and adermatoglyphia: trouble in border!

D. Botsen, O. Bouché, F. Slimano, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR)

A. Lièvre, M. Ducreux, C. Lepage, 2020, Digestive and Liver Disease.

One‐year COVID‐19 outcomes on the oncology care patient pathway: Results of a French descriptive, cross‐sectional comprehensive study (ONCOCARE‐COV)

D. Botsen, O. Bouché, F. Slimano, 2022, Cancer medicine.

Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer

T. Jouary, O. Bouché, R. Bensadoun, 2019, World journal of gastroenterology.

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.

T. Conroy, C. Borg, V. Boige, 2020, Journal of Clinical Oncology.

Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis.

O. Bouché, M. Hebbar, V. Bourgeois, 2017, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial].

B. Chauffert, P. Maingon, P. Rougier, 2011, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

Response to the letter “Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU and infusional 5-FU alone in advanced pancreatic carcinoma patients”, by C. Allior (Ann. Oncol 2004; 15: 1576–1577)

M. Ducreux, P. Rougier, J. Breau, 2004 .

Abstract 2820: Clinical significance of low frequency KRAS and BRAF subclones for advanced colon cancer management

P. Laurent-Puig, P. Srinivasan, D. Link, 2014 .

Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.

C. Tournigand, R. Guimbaud, O. Bouché, 2019, European journal of cancer.

Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial.

P. Laurent-Puig, C. Lepage, J. Emile, 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study—Prodige 14 – ACCORD 21 (METHEP-2), a unicancer GI trial.

M. Ychou, E. Assenat, Y. Bécouarn, 2016 .

Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study).

P. Laurent-Puig, P. Rougier, O. Bouché, 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective observational cohort study (CAPANCOVID)

S. Truant, C. Borg, G. Piessen, 2022, European Journal of Cancer.

Preoperative (preop) radiotherapy (RT) + 5FU/folinic acid (FA) in T3,4 rectal cancers: Preliminary results of the FFCD 9203 randomized trial.

T. Conroy, J. Bosset, O. Bouché, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic Proposals for prioritization from the RENAPE and BIG-RENAPE groups].

O. Bouché, L. Gladieff, O. Glehen, 2020, Journal de chirurgie viscerale.

Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic. Proposals for prioritization from the RENAPE and BIG-RENAPE groups

F. Guyon, M. Pocard, O. Sgarbura, 2020, Journal of Visceral Surgery.

Addition of oxaliplatin (Eloxatine®, LOHP) to the same leucovorin (LV) and 5 fluorouracil (5FU) bimonthly regimens after progression in patients (pts) with metastatic colorectal cancer (MCRC): Preliminary report

O. Bouché, A. Gramont, T. André, 1997 .

Primary prophylactic granulocyte colony-stimulating factor (GCSF) in Gilbert’s disease patients treated with FOLFIRI first line for metastatic colorectal cancer (mCRC): Final results of the FFCD 0604 study.

M. Loriot, P. Laurent-Puig, C. Lepage, 2013 .

Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.

D. Goldstein, O. Bouché, F. Bonnetain, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.

J. Blay, F. Bertucci, A. Cesne, 2016, The Lancet. Oncology.

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.

C. Borg, B. Buecher, O. Bouché, 2018, The Lancet. Oncology.

Prognosis and chemosensitivity of non-colorectal alimentary tract cancers with microsatellite instability.

F. Caroli-Bosc, G. Piessen, M. Perrier, 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Final results of the multicenter randomized phase II PAZOGIST trial evaluating the efficacy of pazopanib (P) plus best supportive care (BSC) vs BSC alone in resistant unresectable metastatic and/or locally advanced gastrointestinal stromal tumors (GIST).

J. Blay, F. Bertucci, A. Cesne, 2015 .

3030 POSTER Randomized strategical trial of chemotherapy in metastatic colorectal cancer (FFCD 2000–05): preliminary results

M. Ducreux, P. Rougier, O. Bouché, 2007 .

Efficacy and Safety of Treatment with Bevacizumab (BEV) + Chemotherapy (CT) Beyond First Progression in Patients (PTS) with Metastatic Colorectal Cancer (MCRC) Previously Treated with BEV + CT: Age Subgroup Analysis From a Randomised Phase III Intergroup Study (ML18147)

O. Bouché, D. Arnold, T. André, 2012 .

[Targeted biotherapies in digestive oncology: management of adverse effects].

O. Bouché, Z. Reguiai, H. Brixi-Benmansour, 2009, Gastroenterologie clinique et biologique.

Dramatic Changes in Oncology Care Pathways During the COVID‐19 Pandemic: The French ONCOCARE‐COV Study

O. Bouché, Y. Merrouche, C. Carlier, 2020, The oncologist.

Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial).

M. Ychou, J. Duffour, M. Ducreux, 2006, Anticancer research.

Reply to E.C. Smyth et al and E. Elimova et al.

M. Ychou, P. Rougier, R. Guimbaud, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

473OThree versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results

M. Ychou, G. Deplanque, Y. Bécouarn, 2017 .

Analysis of plasma protein biomarkers from the CORRECT phase III study of regorafenib for metastatic colorectal cancer.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

D. Goldstein, O. Bouché, F. Bonnetain, 2013, Journal of Clinical Oncology.

Associations between the severity of medical and surgical complications and perception of surgeon empathy in esophageal and gastric cancer patients

S. Msika, A. Lièvre, J. Jougon, 2021, Supportive Care in Cancer.

Treatment intensification by induction chemotherapy (ICT) and radiation dose escalation in locally advanced squamous cell anal canal carcinoma (LAAC): Definitive analysis of the intergroup ACCORD 03 trial.

T. Conroy, M. Ducreux, D. Peiffert, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Feasibility of systematic handgrip strength testing in digestive cancer patients treated with chemotherapy: The FIGHTDIGO study

M. Perrier, C. Mazza, M. Brasseur, 2018, Cancer.

MR imaging of pelvic extraperitoneal masses: A diagnostic approach.

O. Bouché, P. Soyer, C. Hoeffel, 2016, Diagnostic and interventional imaging.

Appendiceal tumors and pseudomyxoma peritonei: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (RENAPE, RENAPATH, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR).

M. Pocard, A. Dohan, O. Bouché, 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Combined Bacterial Meningitis and Infective Endocarditis: When Should We Search for the Other When Either One is Diagnosed?

B. Iung, A. Péchinot, T. Doco‐Lecompte, 2022, Infectious Diseases and Therapy.

702 Randomized phase III trial comparing 5FU bolus and low dose leucovorin versus 5FU bolus plus continuous 5FU infusion and high dose LV in metastatic colorectal cancer

P. Rougier, O. Bouché, L. Bedenne, 1995 .

Phase III preliminary results of preoperative fluorouracil (F) and cisplatin (P) versus surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC 94012-FFCD 9703 trial.

J. Pignon, T. Conroy, M. Ychou, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial

T. Conroy, M. Ychou, M. Ducreux, 2007 .

Nightmares and hallucinations with aprepitant and opium powder: a suspected drug–drug interaction

O. Bouché, F. Slimano, Justine Clarenne, 2018, British journal of clinical pharmacology.

Final results of PRODIGE 9, a randomized phase III comparing no treatment to bevacizumab maintenance during chemotherapy-free intervals in metastatic colorectal cancer.

C. Borel, V. Boige, O. Bouché, 2016 .

PD-0034POPULATION PHARMACOKINETICS ANALYSIS OF REGORAFENIB AND ITS ACTIVE METABOLITES FROM THE PHASE III CORRECT STUDY OF METASTATIC COLORECTAL CANCER

M. Ychou, J. Tabernero, A. Grothey, 2013 .

[HER2 and gastric cancer: a novel therapeutic target for trastuzumab].

F. Penault-Llorca, O. Bouché, O. Bouché, 2010, Bulletin du cancer.

Is antihistaminergic H2 really useful in prevention of hypersensitivity induced by paclitaxel?

O. Bouché, F. Slimano, C. Mongaret, 2016, Supportive Care in Cancer.

FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX‐bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study

C. Tournigand, M. Perrier, D. Botsen, 2022, International journal of cancer.

Impact of Guidelines Regarding Dihydropyrimidine Dehydrogenase (DPD) Deficiency Screening Using Uracil-Based Phenotyping on the Reduction of Severe Side Effect of 5-Fluorouracil-Based Chemotherapy: A Propension Score Analysis

D. Botsen, O. Bouché, F. Slimano, 2022, Pharmaceutics.

Endoscopic ultrasonography is an independent predictive factor of prognosis in locally advanced esophageal cancer. Results from the randomized FFCD 9102 study from the Fédération Francophone de Cancérologie Digestive.

T. Conroy, D. Arsène, O. Bouché, 2008, Gastroenterologie clinique et biologique.

Association of Low Handgrip Strength with Chemotherapy Toxicity in Digestive Cancer Patients: A Comprehensive Observational Cohort Study (FIGHTDIGOTOX)

M. Perrier, E. Bertin, D. Botsen, 2022, Nutrients.

DETECTION AND QUANTIFICATION OF MINORITY KRAS SUBCLONES IN TUMORS USING DROPLET-BASED MICROFLUIDICS: CLINICAL IMPLICATION

P. Laurent-Puig, D. Link, O. Bouché, 2013 .

Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib

M. Ychou, R. Goldberg, H. Lenz, 2013 .

Is Palliative Laparoscopic Hyperthermic Intraperitoneal Chemotherapy Effective in Patients with Malignant Hemorrhagic Ascites?

S. Msika, O. Bouché, R. Kianmanesh, 2012, Case Reports in Gastroenterology.

Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.

J. Pignon, T. Conroy, M. Ychou, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preoperative Chemoradiotherapy (CT-RT) Improves Local Control in T3-4 Rectal Cancers: Results of the FFCD 9203 Randomized Trial

T. Conroy, O. Bouché, P. Romestaing, 2005 .

Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial.

J. Douillard, V. Boige, O. Bouché, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II trial of autologous activated macrophages in advanced colorectal cancer.

O. Bouché, A. Cattan, J. Eymard, 1996, European journal of cancer.

Updated results at 6 year of the GERCOR C96.1 phase III study comparing LV5FU2 to monthly 5FU-leucovorin (mFufol) as adjuvant treatment for Dukes B2 and C colon cancer patients

M. Buyse, O. Bouché, E. Gamelin, 2005 .

Laparoscopic thermal ablation of splenic metastases initial experience and present aspects.

O. Bouché, L. de Mestier, S. Lardière-Deguelte, 2013, Journal of visceral surgery.

Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort

C. Lepage, D. Spaeth, O. Bouché, 2022, Cancer medicine.

Incidence and associated factors of cetuximab-induced hypersensitivity infusion reactions in 1392 cancer patients treated in four French areas: a possible association with Lyme disease?

M. Brasseur, D. Botsen, O. Bouché, 2022, BMC Cancer.

Postoperative circulating tumor DNA detection is associated with the risk of recurrence in patients resected for a stage II colorectal cancer

P. Laurent-Puig, C. Lepage, S. Coutant, 2022, Frontiers in Oncology.

Outcome of erosive/ulcerative reflux oesophagitis in 181 consecutive patients 5 years after diagnosis.

O. Bouché, G. Thiéfin, P. Zeitoun, 1998, Italian journal of gastroenterology and hepatology.

Increased risk of colonic neoplasia in patients with sporadic duodenal adenoma.

O. Bouché, G. Thiéfin, M. Diebold, 2009, Gastroenterologie clinique et biologique.

Prognosis of hepatocellular carcinoma (HCC): Comparison of four staging systems in two French clinical trials

X. Paoletti, P. Rougier, O. Bouché, 2007 .

Multicenter randomized phase III trial comparing tamoxifen alone or with transarterial lipiodol chemoembolization (TLC) for unresectable hepatocellular carcinoma (HCC) in cirrhotic patients

O. Bouché, F. Bonnetain, L. Bedenne, 2005 .

Time course of regorafenib-associated adverse events in the phase III CORRECT study.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.

O. Bouché, A. Bedjaoui, F. Retornaz, 2018, European journal of cancer.

Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial

J. Taïeb, S. Olschwang, V. Boige, 2022, Therapeutic advances in medical oncology.

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.

M. Ychou, E. Assenat, J. Biagi, 2022, JAMA oncology.

Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration

P. Laurent-Puig, M. Ychou, G. Deplanque, 2019, Annals of Oncology.

A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer.

T. Conroy, P. Arveux, C. Mariette, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.

T. Conroy, M. Ychou, C. Bascoul-Mollevi, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anal Carcinoma: Prognostic Value of Endorectal Ultrasound (ERUS). Results of a Prospective Multicenter Study

V. Bardou, O. Bouché, L. Palazzo, 2001, Endoscopy.

Complementary and alternative medicine use by patients with inflammatory bowel disease: results from a postal survey.

O. Bouché, G. Thiéfin, L. Vandromme, 2006, Gastroenterologie clinique et biologique.

Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.

M. Ychou, B. Dréno, P. Gourraud, 2012, The oncologist.

Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms

P. Ruszniewski, O. Bouché, A. Couvelard, 2017, Neuroendocrinology.

Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.

M. Loriot, P. Beaune, D. Trégouët, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era

J. Blay, M. van Glabbeke, F. Bertucci, 2012, Clinical Cancer Research.

Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma.

P. Rougier, V. Boige, O. Bouché, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22).

F. Brunetti, A. Lièvre, C. Lepage, 2020, Annals of surgery.

Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer.

A. Lièvre, M. Ychou, O. Bouché, 2016, Clinical colorectal cancer.

Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting.

J. Blay, B. Bui, A. Italiano, 2016, European journal of cancer.

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

D. Sargent, M. Teufel, M. Ychou, 2015, The Lancet. Oncology.

Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects.

M. Ducreux, A. Cazes, C. Borg, 2017, European journal of cancer.

Time course of regorafenib-associated adverse events in the phase III CORRECT study

M. Ychou, R. Goldberg, H. Lenz, 2013 .

Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group

J. Blay, M. Montemurro, O. Bouché, 2014, BMC Cancer.

Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC)

Daniel J. Sargent, Olivier Bouché, Alberto Sobrero, 2012 .

Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group

J. Blay, M. Montemurro, O. Bouché, 2014, BMC Cancer.

Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR).

E. Baudin, C. Lepage, C. Lombard-Bohas, 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[Primary leiomyosarcoma of the liver 37 years after successful treatment of hereditary retinoblastoma].

O. Bouché, G. Thiéfin, M. Diebold, 1996, Gastroenterologie clinique et biologique.

Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales: utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma.

X. Paoletti, O. Bouché, F. Bonnetain, 2015, The oncologist.

Discoidin Domain Receptor 1 Expression in Colon Cancer: Roles and Prognosis Impact

C. Schneider, S. Dedieu, O. Bouché, 2022, Cancers.

A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy

J. Weidhaas, P. Laurent-Puig, H. Lenz, 2014, Clinical Cancer Research.

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial

C. Borel, C. Lepage, V. Boige, 2020, British Journal of Cancer.

LRP1 expression in colon cancer predicts clinical outcome

C. Schneider, S. Dedieu, O. Bouché, 2018, Oncotarget.

Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status

R. Salazar, P. Laurent-Puig, E. Van Cutsem, 2017, JAMA oncology.

A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).

T. Conroy, M. Ychou, M. Ducreux, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials.

X. Paoletti, P. Rougier, O. Bouché, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Recent insights in the therapeutic management of patients with gastric cancer.

O. Bouché, R. Kianmanesh, L. de Mestier, 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Early surgery for failure after chemoradiation in operable thoracic oesophageal cancer. Analysis of the non-randomised patients in FFCD 9102 phase III trial: Chemoradiation followed by surgery versus chemoradiation alone.

T. Conroy, C. Mariette, O. Bouché, 2015, European journal of cancer.

Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study.

B. Chauffert, J. Bosset, P. Rougier, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ectopic Pregnancy Occurring Under Colorectal Cancer Treatment : A Case Report

O. Bouché, F. Slimano, C. Hoeffel, 2019 .

Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti‐EGFR antibodies in colorectal cancer

A. Lièvre, P. Laurent-Puig, F. Penault-Llorca, 2010, International journal of cancer.

A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen

N. Baroukh, C. Borg, O. Bouché, 2017, BMC Cancer.

Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer

D. Sargent, F. Penault-Llorca, R. Goldberg, 2017, Journal of the National Cancer Institute.

Inflammatory biomarkers to predict postoperative infectious complications after cytoreductive surgery and HIPEC for peritoneal carcinomatosis.

O. Bouché, R. Kianmanesh, Z. Djerada, 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Gastrointestinal stromal tumours (GISTs): French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).

J. Blay, S. Bonvalot, J. Coindre, 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker.

I. Sobhani, G. Chatellier, P. Laurent-Puig, 2016, Clinical chemistry.

Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial.

Pierre Michel, Bernard Denis, Pierre-Luc Etienne, 2011, The Lancet. Oncology.

T. Conroy, C. Borg, O. Bouché, 2021, Clinical colorectal cancer.

Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial

T. Conroy, C. Borel, G. Deplanque, 2019, JAMA oncology.

[A case of chronic ischemic erosive gastropathy healed after surgical revascularization].

O. Bouché, P. Zeitoun, C. Clement, 1989, Gastroenterologie clinique et biologique.

Prognostic value of baseline seric Syndecan‐1 in initially unresectable metastatic colorectal cancer patients: a simple biological score

C. Borg, O. Bouché, F. Ghiringhelli, 2016, International journal of cancer.

Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib

J. Blay, H. Joensuu, A. Italiano, 2017, British Journal of Cancer.

Online supplementary information for the article ‘ Masitinib in advanced gastrointestinal stromal tumor after failure of imatinib : a randomized controlled open-label trial ’

J. Blay, F. Bertucci, A. Cesne, 2014 .

Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors

J. Blay, F. Bertucci, A. Italiano, 2012, Medical Oncology.

Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).

J. Blay, B. Bui, S. Bonvalot, 2010, European journal of cancer.

The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer.

G. Beretta, O. Bouché, M. Geissler, 2010, Cancer treatment reviews.

[Is there still a place for surgery in the treatment of communicating pseudocyst in chronic pancreatitis?].

O. Bouché, J. Flament, J. Palot, 1993, Annales de chirurgie.

Rectal cancer: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).

T. Conroy, J. Bosset, O. Bouché, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study

J. Blay, F. Bertucci, P. Terrier, 2021, Targeted Oncology.

Concurrent losses of skeletal muscle mass, adipose tissue and bone mineral density during bevacizumab / cytotoxic chemotherapy treatment for metastatic colorectal cancer.

V. Baracos, J. Douillard, C. Borg, 2020, Clinical nutrition.

Withholding the Introduction of Anti‐Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild‐Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study)

A. Lièvre, B. Rousseau, C. Vitellius, 2019, The oncologist.

FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.

P. Laurent-Puig, F. Penault-Llorca, C. Borg, 2019, European journal of cancer.

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab

C. Reinhold, C. Borel, C. Lepage, 2019, Gut.

Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?

M. Brasseur, O. Bouché, R. Kianmanesh, 2022, Frontiers in Oncology.

Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial

M. Ychou, E. Assenat, R. Guimbaud, 2022, British Journal of Cancer.

Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic adenocarcinoma.

M. Brasseur, D. Botsen, O. Bouché, 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC).

T. Conroy, O. Bouché, P. Hammel, 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4)

T. Conroy, M. Ychou, O. Bouché, 2017, Oncology.

Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients.

M. Ducreux, P. Rougier, J. Breau, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Resection of small bowel adenocarcinoma metastases: Results of the ARCAD-NADEGE cohort study.

M. Pocard, R. Benamouzig, O. Bouché, 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402).

X. Causse, P. Rougier, F. Caroli-Bosc, 2008, European journal of cancer.

Optical diagnosis of peritoneal metastases by infrared microscopic imaging

Michel Manfait, Valérie Untereiner, Olivier Bouché, 2009, Analytical and bioanalytical chemistry.

Infrared imaging as a cancer diagnostic tool: Introducing a new concept of spectral barcodes for identifying molecular changes in colon tumors

Michel Manfait, Ganesh D Sockalingum, Cyril Gobinet, 2013, Cytometry Part A.

Infrared spectral histopathology for cancer diagnosis: a novel approach for automated pattern recognition of colon adenocarcinoma.

Michel Manfait, Cyril Gobinet, Jayakrupakar Nallala, 2014, The Analyst.

Infrared and Raman Imaging for Characterizing Complex Biological Materials: A Comparative Morpho-Spectroscopic Study of Colon Tissue

M. Manfait, O. Bouché, G. Sockalingum, 2014, Applied spectroscopy.

Infrared spectral imaging as a novel approach for histopathological recognition in colon cancer diagnosis

Michel Manfait, Cyril Gobinet, Olivier Piot, 2012, Journal of biomedical optics.

Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer.

M. Ducreux, O. Bouché, A. de Gramont, 2011, Anticancer research.

Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies

C. Borg, B. Buecher, O. Bouché, 2022, European Journal of Cancer.

Small Bowel Adenocarcinoma in Patients with Crohn's Disease Compared with Small Bowel Adenocarcinoma De Novo

B. Bonaz, J. Faivre, B. Flourié, 2005, Inflammatory bowel diseases.

Author's reply: "A lesion suspected of being a desmoid tumor in the context of familial adenomatous polyposis should be biopsied".

S. Bonvalot, J. Saurin, N. Benech, 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Treatment of carcinoid syndrome

P. Ruszniewski, O. Bouché, J. Wemeau, 2000, Cancer.

Patterns of care and clinical outcomes in primary oesophageal gastrointestinal stromal tumours (GIST): A retrospective study of the French Sarcoma Group (FSG).

J. Blay, F. Bertucci, S. Salas, 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Conservative surgery vs. duodeneopancreatectomy in primary duodenal gastrointestinal stromal tumors (GIST): a retrospective review of 114 patients from the French sarcoma group (FSG).

J. Blay, F. Bertucci, S. Bonvalot, 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs

J. Blay, S. Bonvalot, A. Cesne, 2012, Medical Oncology.

Outcome after surgical treatment of gastrointestinal stromal tumors.

O. Bouché, M. Diebold, J. Delattre, 2007, Gastroenterologie clinique et biologique.

Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment

M. Ychou, E. Assenat, C. Borg, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Sarcomas in patients over 90: Natural history and treatment—A nationwide study over 6 years

J. Blay, F. Bertucci, O. Mir, 2019, International journal of cancer.

Gastrointestinal lymphomas: French Intergroup clinical practice recommendations for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFH).

O. Bouché, C. Hennequin, A. Ruskoné-Fourmestraux, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.

T. Conroy, J. Douillard, V. Boige, 2014, The Lancet. Oncology.

Implications of RAS Mutations on Oncological Outcomes of Surgical Resection and Thermal Ablation Techniques in the Treatment of Colorectal Liver Metastases

O. Bouché, R. Kianmanesh, R. Rhaiem, 2022, Cancers.

COVID-19 epidemic: Proposed alternatives in the management of digestive cancers: A French intergroup clinical point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)

A. Lièvre, C. Lepage, O. Bouché, 2020, Digestive and Liver Disease.

Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER)

J. Blay, K. Hoang-Xuan, J. Bourhis, 2021, European Journal of Cancer.

Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.

T. Conroy, P. Arveux, C. Mariette, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

T. Conroy, C. Bascoul-Mollevi, J. Douillard, 2017, European journal of cancer.

The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma.

X. Paoletti, O. Bouché, F. Bonnetain, 2013, Journal of hepatology.

Characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) who had progression-free survival (PFS) >4 months (m): Subgroup analysis of the phase 3 CORRECT trial

R. Goldberg, H. Lenz, J. Tabernero, 2016 .

Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance

E. Tartour, F. Penault-Llorca, N. Radosevic-Robin, 2019, Gastric Cancer.

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.

T. Conroy, J. Bosset, C. Borg, 2021, The Lancet. Oncology.

Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.

O. Bouché, A. de Gramont, T. André, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Folfox4 with or without Cetuximab (CTX) in Patients (PTS) with Resected Stage III Colon Cancer (CC): Dfs and OS Results and Subgroup Analyses of the PETACC8 Intergroup Phase III Trial

L. Collette, P. Laurent-Puig, C. Lepage, 2012 .

Sorafenib (S) alone versus S combined with gemcitabine and oxaliplatin (GEMOX) in first-line treatment of advanced hepatocellular carcinoma (HCC): Final analysis of the randomized phase II GONEXT trial (UNICANCER/FFCD PRODIGE 10 trial).

M. Ychou, E. Assenat, Y. Bécouarn, 2013 .

Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803.

D. Arsène, P. Rougier, B. Buecher, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial

J. Pignon, T. Conroy, M. Ychou, 2007 .

Final results of a multicenter phase II trial assessing sorafenib (S) in combination with irinotecan (i) as second- or later-line treatment in metastatic colorectal cancer (mCRC) patients (pts) with KRAS-mutated tumors (mt; NEXIRI).

T. Conroy, P. Laurent-Puig, M. Ychou, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlation between muscle mass and handgrip strength in digestive cancer patients undergoing chemotherapy

M. Perrier, C. Mazza, M. Brasseur, 2019, Cancer medicine.

[Cronkhite-Canada syndrome: a new French case].

O. Bouché, G. Thiéfin, M. Diebold, 1999, Gastroenterologie clinique et biologique.

Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High‐Risk Stage III (pT4 and/or N2) Colon Cancer—A UNICANCER GI‐PRODIGE Trial

S. Gill, J. Emile, J. Taïeb, 2019, Clinical colorectal cancer.

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

P. Couzigou, M. Ducreux, C. Borel, 2018, European journal of cancer.

Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma

C. Tournigand, C. Borg, O. Bouché, 2017, Journal of the National Cancer Institute.

Prognostic Value of Angiopoietin-2 for Death Risk Stratification in Patients with Metastatic Colorectal Carcinoma

C. Borg, O. Bouché, F. Ghiringhelli, 2015, Cancer Epidemiology, Biomarkers & Prevention.

Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients.

I. Sobhani, O. Boulat, O. Bouché, 2017, European journal of cancer.

Why do guidelines supersede the conference consensus?: New French recommendations for metastatic colorectal cancer management.

C. Lepage, O. Bouché, T. Aparicio, 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801).

M. Ychou, B. Nordlinger, M. Ducreux, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[Protective effect of appendectomy on the development of ulcerative colitis. A case-control study].

O. Bouché, G. Thiéfin, M. Diebold, 2001, Gastroenterologie clinique et biologique.

Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients.

O. Bouché, M. Ramdani, J. Seitz, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.

M. Buyse, O. Bouché, A. de Gramont, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.

Marc Buyse, Pascal Piedbois, Thierry Andre, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The FREGAT biobank: a clinico-biological database dedicated to esophageal and gastric cancers

S. Msika, T. Conroy, M. Copin, 2018, BMC Cancer.

Lésions planes colorectales: corrélations histo-endoscopiques

O. Bouché, M. Diebold, P. Chevalier, 1999, Acta Endoscopica.

Flat lesions of the colon and rectum: endoscopic and histopathological features

O. Bouché, M. Diebold, P. Chevalier, 1999 .

Colonic Flat Neoplasia: Frequency and Concordance Between Endoscopic Appearance and Histological Diagnosis in a French Prospective Series

O. Bouché, G. Thiéfin, M. Diebold, 2004, The American Journal of Gastroenterology.

Joint model for left‐censored longitudinal data, recurrent events and terminal event: Predictive abilities of tumor burden for cancer evolution with application to the FFCD 2000–05 trial

Virginie Rondeau, Cécile Proust-Lima, Stefan Michiels, 2016, Biometrics.

Sarcopenia: An important prognostic factor for males treated for a locally advanced esophageal carcinoma.

L. Quéro, P. Cattan, O. Bouché, 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[Value and limitation of ultrasound-guided percutaneous drainage in acute lithiasic cholecystitis].

O. Bouché, J. Flament, C. Avisse, 1993, Annales de chirurgie.

Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.

C. Lombard-Bohas, O. Bouché, F. Bonnetain, 2009, European journal of cancer.

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)

F. Bidard, C. Borg, D. Peiffert, 2017, BMC Cancer.

Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP).

M. Ducreux, C. Borg, D. Peiffert, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Reply to R. Glynne-Jones et al.

T. Conroy, M. Ducreux, D. Peiffert, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gastrointestinal stromal tumors (GIST) of the duodenum: A French Sarcoma Group (FSG) retrospective review of 90 patients (pts).

J. Blay, F. Bertucci, A. Le Cesne, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic score for synchronous metastatic rectal cancer: A real-world study.

A. Lièvre, R. Guimbaud, O. Bouché, 2023, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Locoregional relapses in the accord12/0405-prodige 02 study: dosimetric study and risk factors.

N. Magné, L. Quéro, D. Peiffert, 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology.

T. Conroy, P. Rougier, P. Arveux, 2005, Gastroenterologie clinique et biologique.

Bilan initial d’extension locorégionale d’un cancer rectal☆

O. Bouché, P. Soyer, C. Hoeffel, 2014 .

Primary rectal cancer local staging.

O. Bouché, P. Soyer, C. Hoeffel, 2014, Diagnostic and interventional imaging.

Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study

O. Bouché, N. Kerckhove, M. Selvy, 2020, Journal of clinical medicine.

Beneficial influence of microsatellite instability on gelatinase-tissue inhibitors of metalloproteinase balance in colorectal cancer.

W. Hornebeck, O. Bouché, G. Thiéfin, 2007, Anticancer research.

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

N. Magné, B. Chauffert, F. Ducray, 2020, European Journal of Cancer.

PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer.

A. Lièvre, P. Laurent-Puig, H. Sokol, 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)

M. Ychou, E. Assenat, O. Bouché, 2021, Annals of Oncology.

Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial

M. Ychou, E. Assenat, Y. Bécouarn, 2019, British Journal of Cancer.

526O High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours

I. Bièche, S. Chevret, J. Grob, 2020 .

Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).

G. Chatellier, P. Laurent-Puig, H. Blons, 2021, European journal of cancer.

Fully laparoscopic thermo-ablation of liver malignancies with or without liver resection: tumor location is an independent local recurrence risk factor

O. Bouché, D. Sommacale, R. Kianmanesh, 2020, Surgical Endoscopy.

FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): An open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA).

C. Borg, O. Bouché, F. Ghiringhelli, 2015 .

Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study

O. Bouché, F. Bonnetain, J. Taieb, 2017, Oncotarget.

Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR).

C. Tournigand, A. Dohan, P. Chevallier, 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

The prospective French participitation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study in stage III colon cancer: Patients’ characteristics and safety analysis of 3 versus 6 months of adjuvant chemotherapy.

Y. Bécouarn, O. Bouché, F. Bonnetain, 2016 .

Advances in radiological imaging of gastrointestinal tumors.

O. Bouché, C. Hoeffel, C. Marcus, 2009, Critical reviews in oncology/hematology.

Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma

C. Borg, B. Buecher, O. Bouché, 2020, Therapeutic advances in medical oncology.

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial

F. Bidard, C. Borg, B. Buecher, 2020, BMC Cancer.

ACCORD12/0405-Prodige 2 phase III trial neoadjuvant treatment in rectal cancer: Results after 5 years of follow-up.

T. Conroy, O. Bouché, S. Gourgou-Bourgade, 2016 .

PD-1 blockade in solid tumors with defects in polymerase epsilon.

C. Tournigand, I. Bièche, M. Lamendola-Essel, 2022, Cancer discovery.

Identification of circulating biomarkers of Crohn's disease and spondyloarthritis using Fourier transform infrared spectroscopy

D. Loeuille, O. Bouché, F. Slimano, 2022, Journal of Biophotonics.

Microwave Thermoablation of Colorectal Liver Metastases Close to Large Hepatic Vessels Under Pringle Maneuver Minimizes the “Heat Sink Effect”

O. Bouché, D. Sommacale, R. Kianmanesh, 2020, World Journal of Surgery.

Treatment of advanced hepatocellular carcinoma with long-acting octreotide: preliminary results of a randomized placebo-controlled trial (FFCD-ANGH 2001-01 CHOC)

C. Lombard-Bohas, O. Bouché, F. Bonnetain, 2005 .

Renal impairment and abnormal liver function tests in pre-therapeutic phenotype-based DPD deficiency screening using uracilemia: a comprehensive population-based study in 1138 patients

M. Perrier, D. Botsen, O. Bouché, 2023, Therapeutic advances in medical oncology.

[Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].

M. Loriot, J. Thariat, O. Bouché, 2019, Bulletin du cancer.

A phase III randomised trial of LV 5 FU 2 1 irinotecan versus LV 5 FU 2 alone in adjuvant high-risk colon cancer ( FNCLCC Accord 02 / FFCD 9802 )

T. Conroy, M. Ychou, M. Ducreux, 2009 .

Management of gastrointestinal stromal tumours of limited size: proposals from a French panel of physicians.

J. Blay, C. Boustière, S. Bonvalot, 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer

M. Ychou, E. Assenat, D. Botsen, 2021, JAMA network open.

BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study

P. Laurent-Puig, H. Blons, O. Bouché, 2019, Cancers.

Primary tumor resection in colorectal cancer with unresectable synchronous metastases: A review.

J. Vaillant, O. Bouché, J. Spano, 2014, World journal of gastrointestinal oncology.

Beta-blocker exposure and survival outcomes in patients with advanced pancreatic ductal adenocarcinoma: a retrospective cohort study (BETAPANC)

M. Perrier, D. Botsen, O. Bouché, 2023, Frontiers in Pharmacology.

[HER2 and gastric cancer. Recommendations for clinical practice in 2011].

F. Penault-Llorca, J. Emile, O. Bouché, 2011, Annales de pathologie.

Limited Resection Versus Pancreaticoduodenectomy for Duodenal Gastrointestinal Stromal Tumors? Enucleation Interferes in the Debate: A European Multicenter Retrospective Cohort Study

D. Mutter, S. Msika, M. Beuran, 2021, Annals of Surgical Oncology.

A phase II trial of weekly alternating sequential administration of BIBF1120 and BIBW2992 in patients with advanced colorectal cancer

M. Ducreux, O. Bouché, A. Gramont, 2008 .

A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colon Cancer 2 study.

A. Carrato, C. Köhne, P. Reichardt, 2013, European journal of cancer.

Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study

J. Blay, C. Lucchesi, O. Mir, 2019, Clinical Cancer Research.

LBA45A RANDOMIZED MULTICENTRE PHASE II STUDY OF PAZOPANIB PLUS BEST SUPPORTIVE CARE (BSC) VS BSC ALONE IN METASTATIC GASTROINTESTINAL STROMAL TUMORS (GIST) RESISTANT TO IMATINIB AND SUNITINIB

J. Blay, F. Bertucci, B. Bui, 2014 .

Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).

M. Ducreux, B. Buecher, O. Bouché, 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

RAS mutations concordance in circulating tumor DNA (ctDNA) and tissue in metastatic colorectal cancer (mCRC): RASANC, an AGEO prospective multicenter study.

P. Laurent-Puig, H. Blons, O. Bouché, 2017 .

Impact of follow-up on generalized pairwise comparisons for estimating the irinotecan benefit in advanced/metastatic gastric cancer.

M. Buyse, X. Paoletti, O. Bouché, 2021, Contemporary clinical trials.

Cancer de l'estomac

O. Bouché, S. Lagarde, 2005 .

Correction: Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study

J. Blay, C. Lucchesi, O. Mir, 2019, Clinical Cancer Research.

Carcinoembryonic antigen kinetics predict response to first-line treatment in metastatic colorectal cancer: Analysis from PRODIGE 9 trial.

C. Lepage, V. Boige, O. Bouché, 2023, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[Stomach cancer].

O. Bouché, S. Lagarde, 2005, La Revue du praticien.

F. Bidard, C. Borg, D. Peiffert, 2017, BMC Cancer.

Outcome of the nonrandomized patients in the FFCD 9102 trial: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus

T. Conroy, C. Mariette, O. Bouché, 2008 .

Dynamic Prediction of Resectability for Patients with Advanced Ovarian Cancer Undergoing Neo-Adjuvant Chemotherapy: Application of Joint Model for Longitudinal CA-125 Levels

F. Reyal, M. Perrier, O. Bouché, 2022, Cancers.

Dynapenia could predict chemotherapy-induced dose-limiting neurotoxicity in digestive cancer patients

M. Perrier, C. Mazza, M. Brasseur, 2018, BMC Cancer.

F. Bidard, C. Borg, B. Buecher, 2020, BMC Cancer.

Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting.

X. Paoletti, P. Rougier, C. Lombard-Bohas, 2011, Journal of hepatology.

EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib

J. Blay, F. Bertucci, A. Cesne, 2018, PloS one.

cfDNA for accurate determination of RAS and BRAF mutations using OncoBEAM liquid biopsy in metastatic colorectal cancer patients: Results of the real-world multicentric ColoBEAM study.

D. Spaeth, J. Salleron, J. Merlin, 2019, Journal of Clinical Oncology.

[Recommendations for clinical practice: management of stomach adenocarcinoma].

M. Ychou, O. Bouché, Y. Merrouche, 2006, Bulletin du Cancer.

Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status.

R. Salazar, P. Laurent-Puig, J. Tabernero, 2017 .

Genetic counselling referral practices for patients with pancreatic adenocarcinoma: A French retrospective multicentre observational cohort study (CAPANCOGEN).

S. Truant, G. Piessen, M. Perrier, 2023, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study.

P. Laurent-Puig, H. Blons, O. Bouché, 2023, European journal of cancer.

Pancreas cancer-associated polymyositis of the legs regressing after cephalic duodenopancreatectomy: case report and review of the literature.

O. Bouché, R. Kianmanesh, M. Diebold, 2012, JOP : Journal of the pancreas.

Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI).

O. Farges, K. Boudjema, V. Boige, 2021, Clinics and research in hepatology and gastroenterology.

1481PDEfficacy and safety of palbociclib in patients with advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib

J. Blay, A. Cesne, A. Italiano, 2017 .

Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study)

V. Torri, M. Ychou, E. Van Cutsem, 2016, ESMO Open.

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial.

J. Blay, F. Bertucci, B. V. Van Tine, 2014 .

Study of 47 consecutive patients with peptic esophageal stricture compared with 3880 cases of reflux esophagitis

O. Bouché, M. Rejeb, P. Zeitoun, 1992, Digestive Diseases and Sciences.

Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial.

M. Ducreux, P. Rougier, J. Breau, 2006, Gastroenterologie clinique et biologique.

Perioperative Cetuximab with Cisplatin and 5-Fluorouracil in Esogastric Adenocarcinoma: A Phase II Study

C. Lepage, C. Mariette, G. Piessen, 2023, Cancers.

Circulating tumor DNA and circulating tumor cells as predictor of outcome in the PRODIGE14-ACCORD21-METHEP2 phase II trial

W. Cacheux, M. Ychou, M. Stern, 2016 .

Impact of genetic polymorphisms of VEGF pathway on the response to bevacizumab in metastatic colorectal cancer (mCRC): Ancillary study of PRODIGE 9 trial.

S. Olschwang, V. Boige, O. Bouché, 2016 .

Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer.

J. Maurel, O. Bouché, W. Steward, 2009, Journal of pain and symptom management.

Value of diffusion‐weighted and gadolinium‐enhanced MRI for the diagnosis of pelvic recurrence from colorectal cancer

O. Bouché, P. Soyer, C. Hoeffel, 2014, Journal of magnetic resonance imaging : JMRI.

Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib

O. Bouché, R. Coriat, C. Hoeffel, 2015, Journal of cachexia, sarcopenia and muscle.

Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801).

M. Ychou, B. Nordlinger, M. Ducreux, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Is primary tumor resection associated with a longer survival in colon cancer and unresectable synchronous metastases? A 4-year multicentre experience.

O. Bouché, R. Kianmanesh, C. Neuzillet, 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials.

J. Pignon, M. Ducreux, J. Douillard, 2015, European journal of cancer.

Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial

C. Lepage, R. Guimbaud, O. Bouché, 2018, Gastric Cancer.

Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: Results of the randomized phase II PRODIGE 28-time UNICANCER study.

V. Boige, O. Bouché, L. Mineur, 2021, Journal of Clinical Oncology.

LBA46PHASE 2 TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF DOVITINIB IN PATIENTS (PTS) WITH GASTROINTESTINAL STROMAL TUMOR (GIST) REFRACTORY AND/OR INTOLERANT TO IMATINIB (IM)

J. Blay, B. Bui, A. Cesne, 2014 .

[Metastasis of pancreatic cancer in an old cholecystectomy scar].

O. Bouché, G. Thiéfin, M. Diebold, 2005, Gastroenterologie clinique et biologique.

Esophageal cancer - French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR).

L. Quéro, G. Piessen, O. Bouché, 2023, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Multicenter phase III randomized trial comparing laparoscopy and laparotomy for colon cancer surgery in patients older than 75 years: the CELL study, a Fédération de Recherche en Chirurgie (FRENCH) trial

O. Bouché, J. Regimbeau, J. Lefèvre, 2019, BMC Cancer.

46 Randomized phase II trial of LV5FU2, LV5FU2-cisplatinum or LV5FU2-irinotecan in patients (pts) with metastatic gastric or cardial adenocarcinoma (MGA): final results of study FFCD 9803

D. Arsène, O. Bouché, J. Raoul, 2003 .

Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer - PRODIGE 13 a FFCD and Unicancer phase III trial: baseline characteristics

A. Lièvre, C. Lepage, O. Bouché, 2016 .

Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer: The FFCD PRODIGE 13 randomised phase III trial.

C. Lepage, O. Bouché, D. Pezet, 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Additional value of EGFR downstream signaling phosphoprotein expression to KRAS mutation for response prediction to cetuximab in colorectal cancer (CRC)

A. Lièvre, P. Laurent-Puig, F. Penault-Llorca, 2008 .

Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial

M. Ychou, E. Assenat, Y. Bécouarn, 2019, British Journal of Cancer.

[Postoperative imaging after colorectal surgery].

O. Bouché, C. Hoeffel, L. Arrivé, 2009, Journal de Radiologie.

Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome.

P. Ruszniewski, O. Bouché, G. Amouyal, 1995, Surgery.

Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): Results of the randomized UNICANCER PRODIGE 14-ACCORD 21 (METHEP-2) trial.

M. Ychou, E. Assenat, Y. Bécouarn, 2018 .

Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens

X. Paoletti, R. Guimbaud, O. Bouché, 2023, ESMO open.

Quels changements dans le Thsaurus National de Cancrologie Digestive en 2005

M. Ducreux, P. Rougier, D. Peiffert, 2006 .

Clinical experience with sunitinib (SU) in patients over age 65 with metastatic gastrointestinal stromal tumors (GIST): A retrospective study from the French Sarcoma Group (FSG).

J. Blay, F. Bertucci, A. Cesne, 2013 .

FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802).

V. Boige, O. Bouché, F. Ghiringhelli, 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial.

S Michiels, J. Pignon, M. Ducreux, 2013, European journal of cancer.

Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial

J. Pignon, M. Ducreux, C. Lepage, 2019, Expert review of pharmacoeconomics & outcomes research.

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial

C. Borel, C. Lepage, V. Boige, 2020, British Journal of Cancer.

Adjuvant chemotherapy versus perioperative chemotherapy (CTx) for resectable gastric signet ring cell (SRC) gastric cancer: A multicenter, randomized phase II study (PRODIGE 19).

G. Piessen, O. Bouché, C. Eveno, 2019, Journal of Clinical Oncology.

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

J. Reid, A. Lièvre, P. Laurent-Puig, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects.

M. Ducreux, A. Cazes, C. Borg, 2017, European journal of cancer.

Prognostic factors in patients with non resectable metastatic colorectal cancer in the era of targeted biotherapies: relevance of Köhne's risk classification.

O. Bouché, L. de Mestier, C. Delmas, 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02).

I. Sobhani, O. Bouché, P. Michel, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

6091 POSTER Final Results of a Multicentre Phase II Trial Assessing Sorafenib in Combination With Irinotecan as 2nd or Later-line Treatment in Metastatic Colorectal Cancer (mCRC) Patients With KRas Mutated Tumours (mt) (NEXIRI)

P. Laurent-Puig, M. Ychou, O. Bouché, 2011 .

D. Goldstein, O. Bouché, F. Bonnetain, 2016, JAMA.

Value of diffusion‐weighted and gadolinium‐enhanced MRI for the diagnosis of pelvic recurrence from colorectal cancer

O. Bouché, P. Soyer, C. Hoeffel, 2014, Journal of magnetic resonance imaging : JMRI.

Circulating tumor cells in locally advanced pancreatic adenocarcinoma: The ancillary study Circe 07 of the LAP 07 trial.

F. Bidard, J. Pierga, O. Bouché, 2013 .

Advances in radiological imaging of gastrointestinal tumors.

O. Bouché, C. Marcus, V. Ladam-Marcus, 2009, Critical reviews in oncology/hematology.

Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.

T. Conroy, M. Ychou, C. Bascoul-Mollevi, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial.

T. Conroy, M. Ducreux, D. Peiffert, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PRODIGE 2 phase III trial neoadjuvant in rectal cancer: Quality of life and results at 5 years.

T. Conroy, P. Rouanet, O. Bouché, 2016 .

Prevalence of cannabidiol (CBD) consumption and cancer patients' expectations in one oncology day-hospital: A cross-sectional study and questionnaire validation.

M. Perrier, O. Bouché, F. Slimano, 2023, Journal of Oncology Pharmacy Practice.

Cannabidiol–drug interaction in cancer patients: A retrospective study in a real‐life setting

M. Perrier, O. Bouché, F. Slimano, 2023, British journal of clinical pharmacology.

Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era

J. Blay, F. Bertucci, J. Verweij, 2012, Clinical Cancer Research.

Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with advanced pancreatic adenocarcinoma (NCT03665441).

O. Bouché, L. Mineur, J. Metges, 2022, Journal of Clinical Oncology.

Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance

E. Tartour, F. Penault-Llorca, N. Radosevic-Robin, 2019, Gastric Cancer.

Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study.

M. Ducreux, P. Rougier, O. Bouché, 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer.

A. Lièvre, P. Laurent-Puig, C. Lepage, 2023, European journal of cancer.

A. Carrato, C. Köhne, P. Reichardt, 2013, European journal of cancer.

477OBevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18)

T. Conroy, G. Deplanque, C. Borg, 2017 .

PRODIGE 20: Bevacizumab + chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC)--A randomized phase II trial.

O. Bouché, F. Retornaz, J. Taieb, 2015 .

Deep learning for the prediction of the chemotherapy response of metastatic colorectal cancer: comparing and combining H&E staining histopathology and infrared spectral histopathology.

O. Bouché, F. Slimano, O. Piot, 2023, The Analyst.

Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer

V. Boige, O. Bouché, L. Mineur, 2023, JAMA network open.